COMMUNIQUÉS West-GlobeNewswire

Serenity Medical Receives U.S. FDA HDE Approval of the River™ Stent - the First Venous Stent Approved for Severe, Refractory Idiopathic Intracranial Hypertension (IIH)
31/03/2026
Landmark regulatory milestone makes the River stent available for adults with severe IIH – a debilitating, historically undertreated condition – who have failed medical therapy Serenity Medical partners with Radical [...]
BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis
31/03/2026
March 31, 2026 Announcement no. 6 BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis COPENHAGEN, DENMARK, 31 March 2026 – BioPorto A/S (“BioPorto” [...]
Stage4Hope™ Commits $2.5 Million to Memorial Sloan Kettering Cancer Center to Accelerate Breakthrough Cancer Research
31/03/2026
Nonprofit founded by Stage IV lung cancer patient supports precision oncology research aimed at expanding treatment options for advanced cancers ATLANTA, March 31, 2026 (GLOBE NEWSWIRE) -- Stage4Hope™ , a nonprofit [...]
Indiana Overdose Deaths Drop 18% But Deadly New Substances Threaten to Reverse Progress
31/03/2026
The "State of Addiction in Indiana" report highlights significant progress and emerging challenges in the state's battle against addiction. Indianapolis, INDIANA, March 31, 2026 (GLOBE NEWSWIRE) -- Indiana Rehabs has [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
31/03/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 31 March 2026 at 18:00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Jupiter Neurosciences to Present at Emerging Growth Conference on April 2
31/03/2026
JUPITER, FL, March 31, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL ™ , a patented resveratrol-based [...]
Fagron increases share capital through exercise subscription rights
31/03/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 31 March 2026 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of [...]
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
31/03/2026
PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31, 2026 (GLOBE NEWSWIRE [...]
Berry Street Joins Amazon's Health Benefits Connector, Expanding Access to one of Healthcare's Most Underutilized Benefits
31/03/2026
Amazon customers can now discover and enroll in Berry Street's evidence-based nutrition care for weight loss, 30+ conditions NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Berry Street , an AI-powered nutrition therapy [...]
LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program
31/03/2026
Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD’s collaboration with Novo Nordisk NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider [...]
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
31/03/2026
Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Cadrenal’s near-term development priority; broader 12-LOX platform remains a longer-term opportunity PONTE VEDRA, Fla., [...]
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
31/03/2026
Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028 Received FDA Fast Track designation for stenoparib, enabling accelerated [...]
Ambros Therapeutics Announces Notice of Allowance for New U.S. Patent Application Covering Neridronate for Complex Regional Pain Syndrome Type 1
31/03/2026
Enhances Intellectual Property Portfolio and Strengthens the Potential for Neridronate Exclusivity through 2045 IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Ambros Therapeutics, Inc. today announced that the [...]
electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
31/03/2026
ROCKAWAY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Seth Abrams will join [...]
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
31/03/2026
IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2 clinical data show [...]
Catheter Precision Reports 2025 Results and Updates on Strategic Expansion
31/03/2026
Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital Position Unlock Multi- [...]
QHSLab (OTCQB:USAQ) Reports Strong Fiscal 2025 Results with Revenue Growth, Expanding Margins, and Significant Balance Sheet Improvement
31/03/2026
Integrated Service Program Growth Drives Revenue Expansion and Margin Improvement Delivering Improved Profitability and Debt Reduction in Fiscal 2025 Operational Momentum and Balance Sheet Restructuring Position Company [...]
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
31/03/2026
Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian cancer IND submission for ERNA-101 expected in Q3 2026 with first-in- [...]
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
31/03/2026
Model estimates SUBLOCADE ® may reduce staff time and associated costs compared with other medications for opioid use disorder in jails and prisons RICHMOND, Va., March 31, 2026 (GLOBE NEWSWIRE) -- Indivior [...]

Pages